Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome

Abstract

A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab.A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses.The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Maloney D, Lopez A, White C, et al. IDEC-C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin’s lymphoma.Blood. 1997;90:2188–2195.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  2. 2.

    Saleh M, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.Semin Oncol. 2000;27:99–103.

    PubMed  PubMed Central  CAS  Google Scholar 

  3. 3.

    Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.Leukemia. 2002;16:2092–2095.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. 4.

    Cohen Y, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.Hematol J. 2002;3:61–62.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Mori A, Tamaru J-I, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.Eur J Haematol. 2002;68:243–246.

    Article  PubMed  Google Scholar 

  6. 6.

    Cohen Y, Polliack A, Zelig O, Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutininmediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma.Leuk Lymphoma. 2001;42:1405–1408.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia.Isr Med Assoc J. 2002;4:1006–1008.

    PubMed  CAS  Google Scholar 

  8. 8.

    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.Br J Haematol. 2002;116:465–467.

    Article  PubMed  Google Scholar 

  9. 9.

    Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.Blood. 2003;101:3857–3861.

    Article  PubMed  CAS  Google Scholar 

  10. 10.

    Seipelt G, Koschmeider S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.Annal Hematol. 2001;80:170–173.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Anat Galor or Timothy O’Brien.

About this article

Cite this article

Galor, A., O’Brien, T. Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome. Int J Hematol 78, 335–336 (2003). https://doi.org/10.1007/BF02983558

Download citation

Key words

  • Rituximab
  • Immune hemolytic anemia